Efficient systemic DNA delivery to the tumor by self-assembled nanoparticle
Source abstract
Abstract
There are few delivery agents that could deliver gene with high efficiency and low toxicity, especially for animal experiments. Therefore, creating vectors with good delivery efficiency and safety profile is a meaningful work. We have developed a self-assembled gene delivery system (XM001), which can more efficiently deliver DNA to multiple cell lines and breast tumor, as compared to commercial delivery agents. In addition, systemically administrated XM001–BikDD (BikDD is a mutant form of proapoptotic gene Bik) significantly inhibited the growth of human breast cancer cells and prolonged the life span in implanted nude mice. This study demonstrates that XM001 is an efficient and widespread transfection agent, which could be a promising tumor delivery vector for cancer targeted therapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · PARP inhibition in cancer therapy · CRISPR and Genetic Engineering
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (17)
Show source-provided references
1. Braeckmans K, Buyens K, Naeye B, Vercauteren D, Deschout H, Raemdonck K, Remaut K, Sanders NN, Demeester J, De Smedt SC (2010) Advanced fluorescence microscopy methods illuminate the transfection pathway of nucleic acid nanoparticles. J Control Release 148:69–7410.1016/j.jconrel.2010.08.029 ↗
2. Burstein HJ, Winer EP (2009) Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 27:5671–567310.1200/JCO.2009.24.2222 ↗
3. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, Mahlaoui N, Kiermer V, Mittelstaedt D, Bellesme C, Lahlou N, Lefrere F, Blanche S, Audit M, Payen E, Leboulch P, l’Homme B, Bougneres P, Von Kalle C, Fischer A, Cavazzana-Calvo MAubourg P (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:818–82310.1126/science.1171242 ↗
4. Chanda D, Isayeva T, Kumar S, Siegal GP, Szafran AA, Zinn KR, Reddy VV, Ponnazhagan P (2008) Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol Ther 16:871–87810.1038/mt.2008.48 ↗
5. Day CP, Rau KM, Qiu L, Liu CW, Kuo HP, Xie X, Lopez-Berestein G, Hortobagyi GN, Hung MC (2006) Mutant Bik expression mediated by the enhanced minimal topoisomerase II alpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther 13:706–71910.1038/sj.cgt.7700945 ↗
6. Ellisen LW (2011) PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell 19:165–16710.1016/j.ccr.2011.01.047 ↗
7. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–9010.3322/caac.20107 ↗
8. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC (2011) BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 20:341–35610.1016/j.ccr.2011.07.017 ↗
9. Lee M (2009) Hypoxia targeting gene expression for breast cancer gene therapy. Adv Drug Deliv Rev 61:842–84910.1016/j.addr.2009.04.017 ↗
10. Li YM, Wen Y, Zhou BP, Kuo HP, Ding Q, Hung MC (2003) Enhancement of Bik antitumor effect by Bik mutants. Cancer Res 63:7630–7633
11. Li LY, Dai HY, Yeh FL, Kan SF, Lang J, Hsu JL, Jeng LB, Chen YH, Sher YP, Lin WC, Hung MC (2011) Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy. Oncogene 30:1773–178310.1038/onc.2010.558 ↗
12. Sher YP, Tzeng TF, Kan SF, Hsu J, Xie X, Han Z, Lin WC, Li LY, Hung MC (2009) Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival. Oncogene 28:3286–329510.1038/onc.2009.187 ↗
13. Sher YP, Liu SJ, Chang CM, Lien SP, Chen CH, Han Z, Li LY, Chen JS, Wu CW, Hung MC (2011) Cancer-targeted BikDD gene therapy elicits protective antitumor immunity against lung cancer. Mol Cancer Ther 10:637–64710.1158/1535-7163.MCT-10-0827 ↗
14. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235–24410.1016/S0140-6736(10)60892-6 ↗
15. Xie X, Xia W, Li Z, Kuo HP, Liu Y, Ding Q, Zhang S, Spohn B, Yang Y, Wei Y, Lang JY, Evans DB, Chiao PJ, Abbruzzese JL, Hung MC (2007) Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 12:52–6510.1016/j.ccr.2007.05.009 ↗
16. Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, Xiao X, Tang J, Wang X, Liu P, Yang M, Xie Z, Wei W, Spencer DM (2011) Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara(R) for prostate cancer therapy. J Gene Med 13:680–69110.1002/jgm.1620 ↗
17. Xie X, Li L, Xiao X, Guo J, Kong Y, Wu M, Liu W, Gao G, Hsu JL, Wei W, Hung MC (2012) Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther 11:1915–192410.1158/1535-7163.MCT-12-0191 ↗